Triple therapy in refractory detrusor overactivity: a preliminary study.
OBJECTIVE
To evaluate in a prospective study the impact of the "three-drug therapy" (antimuscarinic, alpha-blocker and tricyclic antidepressants) on the treatment of refractory detrusor overactivity (DO).


METHODS
Data from 27 consented patients with refractory DO were available for study. They were asked to complete a daily urinary chart and underwent urodynamic evaluation (UD) before and 60 days after treatment. Response to treatment was considered the presence of one or less involuntary detrusor contractions (IDC) on post-treatment UD. Statistical analysis was performed with Fisher and Mann-Whitney tests, besides Spearman's correlation. P values <0.05 were considered significant.


RESULTS
The mean follow-up was 15 months. The comparison of the daily urinary chart before and after treatment showed significant increase on bladder capacity and decreases on urgency, urge-incontinence and frequency. Objective data from UD showed that the mean maximum bladder capacity (MBC) ranged from 200 to 300 mL (P < 0.001) with treatment. The same trend was observed with the other UD variables. When compared to baseline, the questionnaire OAB-v8 showed significant improvement (P < 0.01). Main side effects comprised dry mouth and constipation (40%), with average scores of 5.16 and 3.08, respectively (visual scale from 0 to 10).


CONCLUSIONS
Triple therapy may be an effective, easily employed and well-tolerated option to refractory DO treatment. More studies are necessary to achieve more consistent data on the matter.
Natalin
Ricardo
R
Division of Urology, University of Campinas, UNICAMP, Campinas, SP, 13073-090, Brazil.
Reis
Leonardo Oliveira
LO
Alpendre
Cristiano
C
Ikari
Lia Y
LY
Prudente
Alessandro
A
D'Ancona
Carlos A L
CA
D000293:Adolescent; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D002648:Child; D017292:Doxazosin / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008297:Male; D008333:Mandelic Acids / Q000627:therapeutic use*; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D011446:Prospective Studies; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D055815:Young Adult
D000317:Adrenergic alpha-Antagonists; D000929:Antidepressive Agents, Tricyclic; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin; D017292:Doxazosin; D007099:Imipramine